Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on June 29, 2020. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in San Francisco, California. Its common stock trades on the NASDAQ Capital Market under the symbol JAGX.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt totals. The report focuses exclusively on a specific transaction regarding an accounts receivable purchase agreement.
Material Changes
On June 29, 2020, the Company amended its accounts receivable purchase agreement dated May 12, 2020, involving Napo Pharmaceuticals, Inc. (a wholly-owned subsidiary) and Oasis Capital, LLC. The material change includes:
- Increased Purchase Price: The purchase price for accounts receivable was increased from 37.5% to 42.5% of the face amount.
- Additional Sales: The Company sold additional accounts receivable under the amended agreement.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the press release furnished as Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the total face value of the additional accounts receivable sold under the amended agreement.
- Confirm the impact of the increased purchase price (42.5%) on the Company's immediate cash inflow and cost of financing.
- Review the full text of the press release (Exhibit 99.1) for details on the remaining terms of the agreement with Oasis Capital, LLC.
- Check subsequent filings for the actual cash proceeds received from this transaction.